Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -58,10 +58,10 @@
58	58	The company generated revenue of $233.2 million and $375.2 million for the years ended December 31, 2020 and 2021, respectively. As of December 31, 2021, the company had a total of 36 partners for whom the company was conducting antibody discovery activities. For the year ended December 31, 2020, three of its partners accounted for 35%, 25% and 14% of its research fees revenue and eight partners accounted for the remaining 26% of research fees revenue. For the year ended December 31,2020 the company recognized its first clinical milestone payments and royalty revenue streams, totaling $213.3 million, exclusively from its partnership with Lilly. For the year ended December 31, 2021, four of its partners accounted for 29%, 17%, 11% and 10% of its research fees revenue and 12 partners accounted for the remaining 33% of research fees revenue. For the year ended December 31, 2021, the company recognized milestone payments of $7.0 million and royalty revenue of $327.3million exclusively from its partnership with Lilly.
59	59
60	60
61		-The company incurred research and development expenses of$29.4 million and $62.1 million for the years ended December 31, 2020 and 2021, respectively. The company incurred general and administrative expenses of $11.9 million and $41.8 million for the years ended December 31, 2020 and 2021, respectively.
	61	+The company incurred research and development expenses of $29.4 million and $62.1 million for the years ended December 31, 2020 and 2021, respectively. The company incurred general and administrative expenses of $11.9 million and $41.8 million for the years ended December 31, 2020 and 2021, respectively.
62	62
63	63
64		-The company's net earnings for the year ended December 31, 2020 was $118.9 million and its net earnings for the year ended December 31, 2021 was $153.5 million.As of December 31, 2021, the company had accumulated earnings of $267.7 million and the company had balance of cash, cash equivalents, and marketable securities totaling$723.0 million.
	64	+The company's net earnings for the year ended December 31, 2020 was $118.9 million and its net earnings for the year ended December 31, 2021 was $153.5 million. As of December 31, 2021, the company had accumulated earnings of $267.7 million and the company had balance of cash, cash equivalents, and marketable securities totaling $723.0 million.
65	65
66	66
67	67	[[image:ABCL2.jpg]]